| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702762 | Urologic Oncology: Seminars and Original Investigations | 2017 | 8 Pages |
Abstract
Our data indicate that miR-144-3p, which is significantly up-regulated in ccRCC plasmas and tissues, particularly with advanced pT stage, is a novel and excellent plasma biomarker for the diagnosis of ccRCC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Ning Ph.D., An-Ming M.S., Bin M.S., Lin M.S., Yu-Chen M.D., Yan Ph.D., Ru-Lin Ph.D., San-Tao M.S., Guang-Hua Ph.D., Hai-Long Ph.D., Chang-Fei M.S., Wei-Wei Ph.D., Hang-Chuan Ph.D., Hong-Mei Ph.D., Xiao-Ping M.D., Ph.D.,